BiVictriX Therapeutics Plc's (LON:BVX) Profit Outlook

We feel now is a pretty good time to analyse BiVictriX Therapeutics Plc's (LON:BVX) business as it appears the company may be on the cusp of a considerable accomplishment. BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The UK£9.1m market-cap company’s loss lessened since it announced a UK£2.5m loss in the full financial year, compared to the latest trailing-twelve-month loss of UK£2.3m, as it approaches breakeven. Many investors are wondering about the rate at which BiVictriX Therapeutics will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.

View our latest analysis for BiVictriX Therapeutics

BiVictriX Therapeutics is bordering on breakeven, according to some British Biotechs analysts. They anticipate the company to incur a final loss in 2024, before generating positive profits of UK£2.9m in 2025. The company is therefore projected to breakeven around 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 64% is expected, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

We're not going to go through company-specific developments for BiVictriX Therapeutics given that this is a high-level summary, though, bear in mind that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

One thing we’d like to point out is that BiVictriX Therapeutics has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which usually has a high level of debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

There are too many aspects of BiVictriX Therapeutics to cover in one brief article, but the key fundamentals for the company can all be found in one place – BiVictriX Therapeutics' company page on Simply Wall St. We've also put together a list of essential factors you should further examine:

1. Historical Track Record: What has BiVictriX Therapeutics' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on BiVictriX Therapeutics' board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.